Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2026)
Xeris Biopharma Holdings (XERS) reported Retained Earnings of -$24000.0 for Q1 2026, up 100.0% on a YoY basis from -$12000.2 in Q1 2025, and up 100.0% quarter-over-quarter from -$671.3 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings has reported Retained Earnings for 7 years, with the latest figure at -$24000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 100.0% year-over-year to -$24000.0; the trailing twelve-month figure through Mar 2026 stood at -$24000.0 (up 100.0% YoY), and the FY2025 full-year result was -$671.3 million, down 2685128.0% from the prior year.
- Retained Earnings for Q1 2026 stood at -$24000.0, up from -$671.3 million in the prior quarter.
- The five-year high for Retained Earnings was -$24000.0 in Q1 2026, with the low at -$683.0 million in Q2 2025.
- Historically, Retained Earnings has averaged -$436.3 million across 5 years, with a median of -$591.4 million in 2023.
- Annual changes were most pronounced in 2025 — Retained Earnings tumbled 2685128.0% — and 2026, when it soared 100.0%.
- Xeris Biopharma Holdings' Retained Earnings stood at -$554.8 million in 2022, then fell by 11.22% to -$617.0 million in 2023, then soared by 100.0% to -$25000.0 in 2024, then plunged by 2685128.0% to -$671.3 million in 2025, then soared by 100.0% to -$24000.0 in 2026.
- The last three Retained Earnings figures came in at -$24000.0 (Q1 2026), -$671.3 million (Q4 2025), and -$25000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -2.51 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -772.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -10.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 683,383.23 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 589.60 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -2.13 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -2.91 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -1.87 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -4.41 Mn |
| 10 | Xeris Biopharma Holdings | 1.07 Bn | 954.87 Mn | 72.55 Mn | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24,000.00 |
| Dec 31, 2025 | -671.31 Mn |
| Sep 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -683.01 Mn |
| Mar 31, 2025 | -681.08 Mn |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -666.70 Mn |
| Jun 30, 2024 | -651.00 Mn |
| Mar 31, 2024 | -636.00 Mn |
| Dec 31, 2023 | -617.03 Mn |
| Sep 30, 2023 | -603.60 Mn |
| Jun 30, 2023 | -591.45 Mn |
| Mar 31, 2023 | -29,000.00 |
| Dec 31, 2022 | -554.77 Mn |
| Sep 30, 2022 | -541.80 Mn |
| Jun 30, 2022 | -520.01 Mn |
| Mar 31, 2022 | -66,000.00 |
| Dec 31, 2021 | -31,000.00 |
| Sep 30, 2021 | -409.30 Mn |
| Dec 31, 2020 | -337.39 Mn |